# SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)

> **NCT00739674** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 992 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])
- **BEHAVIORAL:** Low Salt Diet

## Key facts

- **NCT ID:** NCT00739674
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-01
- **Primary completion:** 2009-07-01
- **Final completion:** 2010-01-01
- **Target enrollment:** 992 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739674, "SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00739674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*